Case Report: Acquired CDKN2A/B deletion and mTOR inhibitor resistance in TSC2-mutant metastatic epithelioid angiomyolipoma
Shuai He, Jing Yang, Jiguang Yang, Chunxia Li, Juan Shen, Xiaolong Ye, Zuping Liu, Wenhao Shen, Jun Zheng, Yongquan Wang · 2026
Read Case Report: Acquired CDKN2A/B deletion and mTOR inhibitor resistance in TSC2-mutant metastatic epithelioid angiomyolipoma by Shuai He, Jing Yang, Jiguang Yang, Chunxia Li, Juan Shen, Xiaolong Ye, Zuping Liu, Wenhao Shen, Jun Zheng, Yongquan Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13550966.txt.
Description
Shuai He and co-authors report a cancer case in which a targeted drug stopped working, in a paper published in 2026. The patient, a 30-year-old woman, had a rare spreading tumor with mutations in the TSC2 gene. A drug that blocks the mTOR pathway first wiped out visible disease.
Sixteen months later the cancer grew again. A new biopsy showed the original mutations plus a fresh loss of two genes, CDKN2A and CDKN2B, which normally restrain cell division. Growth markers had risen and the tumor's staining pattern had shifted. The authors suggest the gene loss may help explain the drug resistance and the more aggressive behavior. They propose that drugs aimed at the CDK4 and CDK6 proteins deserve study in such cases.
Catalog record
| CREATOR | Shuai He, Jing Yang, Jiguang Yang, Chunxia Li, Juan Shen, Xiaolong Ye, Zuping Liu, Wenhao Shen, Jun Zheng, Yongquan Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 19 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |